CD123 TARGETED IMMUNOTHERAPIES

The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated...

Full description

Saved in:
Bibliographic Details
Main Authors POGSON, Mark, MACEDO, Chelsie, JARJOUR, Jordan, CRAGO, William, LEUNG, Wai-Hang, TIMMER, John C, JONES, Kyle, HOLLANDS, Andrew, MA, Milton, ECKELMAN, Brendan P
Format Patent
LanguageEnglish
French
Published 12.11.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides improved CD123 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. La présente divulgation concerne des polypeptides ciblant CD123 améliorés et des compositions pour des thérapies adoptives par lymphocytes T pour le traitement, la prévention ou l'amélioration d'au moins un symptôme d'un cancer, d'une maladie infectieuse, d'une maladie auto-immune, d'une maladie inflammatoire, d'une immunodéficience ou d'un état associé.
Bibliography:Application Number: WO2020US31794